Lawrence Marnett
-
Better adenoma detection
Fluorescent nanoparticles clearly identified colonic adenomas — precursors to colorectal cancer — in mice, and the formulation should translate to clinical use in humans. Read MoreMay 4, 2023
-
Potential probe for early ovarian cancer
Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme. Read MoreJune 20, 2019
-
Energetic gene switch
James Galligan and Lawrence Marnett have discovered a new histone modification that can affect gene expression. Read MoreAugust 30, 2018
-
Mitochondrial mutations and disease
New findings suggest that oxidative stress damages mitochondrial DNA, and they link this damage to a disease state. Read MoreFebruary 22, 2018
-
Imaging probe for retinal disease
An imaging probe developed at Vanderbilt detects retinal inflammation early and may allow therapeutic intervention to prevent blindness. Read MoreOctober 12, 2016
-
The yin and yang of COX-2
New findings add to the understanding of how the enzyme COX-2 works, which is critical to the development of COX-2-targeted anti-inflammatory drugs. Read MoreOctober 2, 2015
-
Lit up COX-2 cancer probe
A new imaging probe developed by Vanderbilt investigators enhances tumor visibility and has broad applications in diagnosing and monitoring patients with cancer. Read MoreJune 17, 2015
-
Vanderbilt scientists discover potential new way to treat anxiety
Chemically modified inhibitors of the COX-2 enzyme relieve anxiety behaviors in mice by activating natural “endocannabinoids” without gastrointestinal side effects, Vanderbilt University scientists will report next week. Read MoreAugust 5, 2013
-
Study puts a new spin on ibuprofen’s actions
Vanderbilt University investigators have discovered surprising new insights into the actions of NSAIDs. Read MoreSeptember 29, 2011